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thetic valves (OR, 1.61; 95% CI, 1.27-2.04; P< 0.0001). The risk difference decreased 
to 16% during 30 days after the surgery date (OR, 1.18; 95% CI, 1.09-1.28; P< 0.0001). 
There were no differences within 31 to 365 days after the surgery date and within 
the 30 days post-discharge. Risk of operative mortality was 19% higher for mechani-
cal valves than for bioprosthetic valves (OR, 1.21; 95% CI, 1.13-1.30; P< 0.0001). The 
number needed to treat with mechanical valves to observe one additional death 
on the surgery date was 290. Consistent findings were observed in subgroup analy-
ses of patients who underwent concurrent AVR and Coronary Artery Bypass Graft 
(CABG), but not in isolated AVR subgroup. ConClusions: In this cohort analysis 
of Medicare beneficiaries, mechanical aortic valves were associated with a higher 
risk of death on the surgery date and within the 30 days following surgery when 
compared with bioprosthetic aortic valves among patients who underwent concur-
rent AVR and CABG, but not isolated AVR.
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objeCtives: The objectives were to determine the comparative effectiveness 
of Angiontensin II receptor blockers (ARB) and Angiotensin converting enzyme 
Inhibitors (ACEI) in patients with heart failure (HF), and to determine comparative 
effectiveness of individual drugs within classes - ACEIs and ARBs. Methods: A 
retrospective national cohort of Veterans Affairs patients with HF from 1997 to 
2002 was employed. Exposure to ARB therapy or ACEI therapy was seen in 2002. 
Mortality as outcome was assessed within one year of follow-up. Multivariate Cox 
proportional hazards regression and propensity scoring techniques were employed 
for data analysis, adjusting for 45 patient risk factors including socio-demograph-
ics, co-morbidities, co-medications and severity of illness. Results: Out of a total 
cohort of 299,462 patients, 200,552 patients were on either ACEIs or ARBs. 187,478 
patients were taking ACEIs and 25,987 were taking ARBs. There was no significant 
difference in reduction of risk of mortality with use of ARBs versus ACEIs (HR 0.955, 
95% CI: 0.907-1.006). Results from stratification using propensity score analysis also 
suggest the same. Patients were stratified into 5 groups based on propensity to 
receive ARB. Proportion of patients that died was not significantly different for ACEI 
and ARB in four out of the five groups. Among ACEIs, Enalapril (HR 0.715, 95% CI: 
0.584-0.876), Fosinopril (HR 0.778, 95% CI: 0.729-0.830) and Lisinopril (HR 0.784, 95% 
CI: 0.740-0.831) were significantly better than Captopril in reducing risk of mortal-
ity. Among ARBs, Candesartan (HR 0.847, 95% CI: 0.751-0.994) and Irbesartan (HR 
0.892, 95% CI: 0.795-1.00) were significantly better than Losartan in reducing risk 
of mortality. ConClusions: Results from the study suggest that ARBs are equally 
effective as ACEIs in reducing risk of mortality in heart failure patients and there 
are significant differences in effectiveness of individual drugs within ACEIs and 
ARBs in reducing risk of mortality in heart failure.
PCV24
multifaCeted interVentions imProVe mediCation adherenCe in 
mediCaid Patients PresCribed hyPoglyCemiCs, statins, and/or 
antihyPertensiVes
Gao W.1, Keleti D.1, Donia T.1, Downey T.W.1, Megargell L.2, Kreitman J.3, Michael K.E.1, Gelzer 
A.D.1
1The AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA, 2PerformRx, Philadelphia, 
PA, USA, 3AmeriHealth Caritas Pennsylvania, Harrisburg, PA, USA
objeCtives: To measure the effectiveness of adherence interventions for oral hypo-
glycemics, antihypertensives, and statins on medication adherence and acute hos-
pitalization (emergency room [ER] and inpatient) in three Medicaid managed care 
organizations (MCOs) in Southeastern Pennsylvania (SEPA) and Lehigh/Capital-New 
West Pennsylvania (LCNWPA). Methods: One-year follow-up analysis of prescrip-
tion and hospitalization member data with prescription fills for hypoglycemics, 
statins, and/or antihypertensives from January 1 to December 31, 2012. Thirty inter-
ventions— categorized as general interventions (GI) for all subjects and personalized 
interventions (PI) for higher-risk care-managed subjects—were implemented to 
improve 2013 adherence. Medication adherence (proportion of days covered [PDC]; 
baseline inclusion criterion: 20%–67%) and acute hospitalization rates (utilization 
per thousand members per year) were calculated at baseline and at one-year post-
intervention. Results: Of 6,382 participants (1,607 LCNWPA; 4,775 SEPA), 1,044 
were PI subjects (579 LCNWPA; 465 SEPA). SEPA and LCWPA member profiles were 
demographically similar to one another, except regarding race and ethnicity. The 
PDC rate improvements for all three medication classes were 13.14% for LCNWPA 
and 14.15% for SEPA (P< 0.01 for both), accompanied by significant increases in 
inpatient admissions (+11.0% and +1.9%, respectively; P< 0.01 for both); the SEPA 
cohort also experienced an increase in inpatient admissions—small in magnitude, 
but statistically significant (+0.3%; P< 0.01). Improvements in mean PDC were sig-
nificantly greater in PI than GI subjects (LCNWPA: 16.12% vs. 11.46%, P< 0.01; SEPA: 
20.95% vs. 13.42%, P< 0.01), but increases in acute hospitalization were also signifi-
cantly greater (P< 0.01 for all, except ER-[LCNWPA]) due to selection bias. Subjects 
demonstrating improvements in 2013 PDC rates displayed comparable changes in 
acute hospitalization rates as their non-improving counterparts. ConClusions: 
Multifaceted MCO-implemented adherence interventions significantly improved 
medication adherence in Medicaid participants, especially in higher-risk subjects. 
However, these PDC improvements were not necessarily translated into measurable 
reductions in acute hospitalization over the one-year post-intervention timeframe.
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objeCtives: Adults undergoing cardiac surgery (CS) frequently receive intrave-
nous (IV) crystalloids perioperatively for resuscitation and maintenance of adequate 
circulating volume. Use of balanced crystalloids has been associated with more 
favorable outcomes versus non-balanced crystalloids, however studies compar-
ing outcomes among CS patients receiving different types of balanced crystalloids 
are lacking. We conducted a retrospective analysis using a large de-identified US 
electronic health record database to investigate differences in major outcomes 
among patients receiving different types of balanced crystalloids (during and up to 
72 hours post-CS). Methods: Patients undergoing CS between January 2009 and 
June 2013 were included if they received ≥ 500mL balanced crystalloid within 1 day 
following surgery and survived ≥ 1 day. Patients with a length-of-stay > 30 days, 
undergoing multiple CS procedures, or receiving > 1L fluid on the day preceding 
surgery were excluded (restricting the cohort to those undergoing routine elec-
tive CS). Following univariate descriptions, propensity-score matching was carried 
out and outcomes were compared (adjusted for confounders). Models compared 
patients receiving Plasma-Lyte® or Normosol® (PL-N) versus Lactated Ringer’s (LR), 
as these solutions differ in their electrolyte composition. The primary outcome 
was 90-day in-hospital mortality (during index hospitalization or readmission). 
Additional outcomes included daily per-patient costs, renal, cardiac and vascular 
events, respiratory failure, and infectious, gastrointestinal, and neurologic compli-
cations. Results: 4,089 patients met inclusion criteria. We selected 299 patients 
receiving PL-N and matched them using propensity-score-based greedy matching 
methods with an equal number receiving LR. There were significant regional dif-
ferences in the choice of crystalloid (PL-N more common in the South). Odds of 
90-day mortality following the receipt of PL-N versus LR were 0.96 [0.94;0.97]. Daily 
per-patient costs and odds of respiratory failure were significantly lower among 
patients receiving PL-N. ConClusions: Receipt of PlasmaLyte® or Normosol® 
rather than LR perioperatively in CS patients may be associated with improved 
outcomes and lower costs.
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objeCtives: First, to examine how both the effectiveness of valsartan centric regi-
mens and the patients-related factors affect the control rates of the Systolic Blood 
Pressure (SBP), Diastolic (DBP) and combined SBP/DBP; specifically for Belgian patients 
with a history of failed or intolerant anti-hypertensive treatment. Secondly, to assess 
the effectiveness of valsartan treatment groups and the related factors concerning 
a patients’ total cardiovascular risk (TCVR) residuals. Lastly, to attempt to estimate 
the cost avoidance factor associated with taking varying levels of valsartan treat-
ment doses. Methods: This research took the form of a secondary-data analysis. 
The variants of valsartan doses given to patients included: valsartan monotherapy, 
a combination of valsartan with hydrochlorothiazide, and a combination of valsar-
tan with amlodipine. We applied Bailey’s approach, using Kaplan-Meier curves to 
estimate the distribution of treatment intensity at which the target rates of SBP, DBP 
and SBP/DBP were achieved. Results: A total of 17,683 patients were included in 
this study. Overall, there was a statistically significant increase in the proportion of 
patients with controlled SBP, DBP and combined SBP/DBP after 90 days of starting on 
valsartan-centric regimens (p< 0.001). Both older age and the presence of diabetes 
were associated with a lower control rate of SBP, DBP and combined SBP/DBP (P< 0.05). 
Substantial reductions in total cardiovascular risk, particularly in the very high added-
risk category was observed and an increase in the low added risk TCVR (p< 0.001). 
The associated cost avoidance with varying levels of treatment intensity were dose 
related. ConClusions: Valsartan-centric regimens were effective in increasing the 
control rates of SBP, DBP and combined SBP/DBP in the real practice for patients whose 
prior treatment failed. Not only did valsartan regimens improve the BP control rate, 
they also reduced the TCVR residuals. Additionally, substantial cost avoidance was 
found to be associated with the use of higher levels of treatment intensity.
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objeCtives: To compare early mortality after aortic valve replacement (AVR) 
between the recipients of mechanical and bioprosthetic aortic valves. Methods: 
A retrospective analysis of patients 65 years or older in the 2006-2011 Medicare 
databases who underwent AVR. In the mixed effects models adjusting for physi-
cian and hospital random effects, we estimated odds ratios (OR) of early mortality, 
comparing mechanical versus bioprosthetic valves. Early mortality was measured as 
death on the surgery date, death within 1-30 and 31-365 days after the surgery date, 
death within 30 days after the hospital discharge date and operative mortality (death 
within 30 days following surgery, or at discharge, whichever is longer). Results: 
Of the 66,453 Medicare beneficiaries included in the study, 19,190 (28.88%) received 
a mechanical valve and 47,263 (71.12%) received a bioprosthetic valve. The risk of 
death on the surgery date was 60% higher for mechanical valves than for biopros-
